Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-3475 versus docetaxel in previously treated PD-L1-positive non-small cell lung cancer
NL-OMON47020Phase 2Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Oct 2013
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pembrolizumab and docetaxel in non-small cell lung cancer (NSCLC) (4 arms), sponsored by Merck & Co. Primary endpoints: Overall survival, Progression-free survival and 1 more. Started Oct 2013; status: active, not recruiting.
02
Drugs
pembrolizumabdocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON47020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47020.